TABLE 4.

Possible indications for the use of anti-Pneumocystis prophylaxis

Solid-organ transplant recipients and allogeneic HSCT or bone marrow transplant recipients with institutional incidence of ≥5% or in high-risk patients:

History of PCP or frequent opportunistic infections

With invasive CMV infection or at high risk for CMV disease

During intensified immune suppression for acute allograft rejection or GVHD

Individuals receiving anti-T-cell therapies

Autologous bone marrow transplant recipients with leukemia or lymphoma, undergoing intensive conditioning or graft manipulation, or after fludarabine or 2-CDA

Individuals with prolonged neutropenia (if marrow suppression is tolerable)

Individuals with corticosteroid doses of ≥20 mg of prednisone per day for ≥2-3 wk